EN DE
Watch Marker Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Marker Therapeutics Inc (MRKR) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Marker Therapeutics Inc stock $0.86, price $0.89, that is 3.5% below the price, quality 29 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MT Marker Therapeutics Inc logo Thin data Nov 9, 2026

Marker Therapeutics Inc

MRKR · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value $0.8585 · Fairly valued
Mixed Growth (revenue 5y +50.0 %/yr in USD)
Mixed vs. peers (3/7)
Revenue last quarter 51% below a year ago.
Quality 29/100
Negative free cash flow
Narrow moat 6/100
Thin data
⚠ Dilution
Watch Marker Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$20.70 $0.7100 Fair Value $0.8585 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range $0.7100 – $20.70 · fair‑value band $0.5610 – $1.07 · the $0.8900 price screens above the $0.8585 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Marker Therapeutics in your weekly email

Every Wednesday you see whether Marker Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.

Show moreShow less

The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.

It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes.

The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Stock analysis

Marker Therapeutics Inc (MRKR) currently trades at $0.8900, while our model-based Fair Value estimate is $0.8585, so the stock looks roughly fairly valued today (gap 3.7%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.5610 (bear) to $1.07 (bull), the price of $0.8900 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Marker Therapeutics Inc reported revenue of $3.5M in FY2025 versus $1.2M in FY2021, a compound +30.0%/yr. Reported net income was −$12.2M in FY2025.

Key figures

Market cap $17.2M Micro · P/S ratio 4.20 · EPS (TTM) $−0.4200 · Return on equity −76.9% · Return on assets (EBIT) −63.7% (5-year average) · Operating margin −268% · Revenue (TTM) $3.5M · Revenue growth (YoY) −51.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (medium confidence).

What moves the price

The share trades about 59% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −4%, MRKR screens richer than that median.

Fair Value models

Bear $0.5610 Fair Value $0.8585 Bull $1.07
Price $0.8900 · Downside -3.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.6600 $1.01 $1.26 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.6600 $1.01 $1.26 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 7
How calm the share price moves, does not count
Price momentum 20
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−46.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+50.0%
Start year 2020 (pandemic)
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,188.3% (2020) → −363.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch MRKR, get fair value alerts →

Compare Marker Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −3.5% · Above median
Profitability
Return on assets −63.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −51.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.02× · Cheapest 25%
P/S (12 months) 4.85× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)29 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs MRKR
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs MRKR
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs MRKR
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs MRKR
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs MRKR
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs MRKR
argenx SE ARGX $927.21 $908.40 −2% vs MRKR
CSL Limited CSL A$200.77 A$183.04 −9% vs MRKR
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs MRKR
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs MRKR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Marker Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Marker Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/MRKR

Frequently asked questions

Is Marker Therapeutics Inc (MRKR) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $0.8585 versus a price of $0.8900, about 4% lower (fairly valued).
What is the fair value of MRKR?
Our model-based fair value for Marker Therapeutics Inc is $0.8585 (as of Nov 9, 2026), built from audited fundamentals. The current price: $0.8900.
What is the quality score of MRKR?
Marker Therapeutics Inc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Marker Therapeutics Inc (MRKR)?
Our model-based price target is the fair value of $0.8585 (as of Nov 9, 2026) from 1 valuation models. Cautious scenario $0.5610, optimistic scenario $1.07. It is a calculation from audited fundamentals, not an analyst target.
What is the Marker Therapeutics Inc stock forecast for 2026?
Our models put fair value at $0.8585, about 4% lower versus a price of $0.8900 (fairly valued). Cautious scenario $0.5610, optimistic scenario $1.07. The calculation is refreshed regularly with new filings.
What is the revenue of Marker Therapeutics Inc (MRKR)?
Marker Therapeutics Inc reported trailing-twelve-month revenue of about $3.5M (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Marker Therapeutics Inc (MRKR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Marker Therapeutics Inc it is $0.8585 per share (as of Nov 9, 2026), against a price of $0.8900. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Marker Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, MRKR trades above its calculated fair value: price $0.8900, fair value $0.8585, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MRKR?
No. The price is what the market pays today ($0.8900); the fair value is what the company's own numbers justify ($0.8585). For Marker Therapeutics Inc the two are $0.0315 per share apart. That gap is exactly why we show both numbers side by side.
How much is Marker Therapeutics Inc worth?
The market values Marker Therapeutics Inc at about $17.2M (market capitalisation, as of Nov 9, 2026). Per share that is $0.8900; our models calculate a fair value of $0.8585 per share.
What do the bullish and bearish scenarios say about MRKR?
Our models span a range for Marker Therapeutics Inc: cautious scenario $0.5610, base $0.8585, optimistic $1.07 per share (as of Nov 9, 2026, price $0.8900). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Marker Therapeutics Inc (MRKR)?
Balance-sheet figures for Marker Therapeutics Inc (as of Nov 9, 2026): return on equity −76.9%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is MRKR from its 52-week high?
Marker Therapeutics Inc trades at $0.8900, about 59% below its 52-week high of $2.19 and 3% above the low of $0.8600 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8585 is for.
Which stocks are comparable to Marker Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Marker Therapeutics Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $0.8900, calculated fair value $0.8585 (−4%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MRKR calculated?
We run Marker Therapeutics Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.8585 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Marker Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Marker Therapeutics Inc (MRKR)?
The closing price on Nov 6, 2026 was $0.8900. Our model-based fair value is $0.8585, about 4% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Marker Therapeutics Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($0.5610 to $1.07) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Marker Therapeutics Inc

How large is the market capitalisation of Marker Therapeutics Inc (MRKR)?
The market capitalisation of Marker Therapeutics Inc is $17.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Marker Therapeutics Inc (MRKR)?
The price-to-sales ratio of Marker Therapeutics Inc is 4.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Marker Therapeutics Inc (MRKR)?
Earnings per share at Marker Therapeutics Inc are $−0.4200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Marker Therapeutics Inc (MRKR)?
The return on equity (ROE) of Marker Therapeutics Inc is −76.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Marker Therapeutics Inc (MRKR)?
On an EBIT basis the return on assets of Marker Therapeutics Inc is −63.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Marker Therapeutics Inc (MRKR)?
The operating margin of Marker Therapeutics Inc is −268% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Marker Therapeutics Inc (MRKR)?
Revenue at Marker Therapeutics Inc is growing −51.0% versus a year earlier (3y avg +0.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Marker Therapeutics Inc (MRKR) generate?
The free cash flow of Marker Therapeutics Inc is −$12.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Marker Therapeutics Inc (MRKR) hold?
Marker Therapeutics Inc holds more cash than debt, $16.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Marker Therapeutics Inc in the live analysis

One click puts Marker Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.